Prostate cancer and microfluids.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
08 2021
Historique:
received: 12 12 2020
revised: 14 03 2021
accepted: 16 03 2021
pubmed: 4 5 2021
medline: 5 1 2022
entrez: 3 5 2021
Statut: ppublish

Résumé

Microfluidic systems aim to detect sample matter quickly with high sensitivity and resolution, on a small scale. With its increased use in medicine, the field is showing significant promise in prostate cancer diagnosis and management due, in part, to its ability to offer point-of-care testing. This review highlights some of the research that has been undertaken in respect of prostate cancer and microfluidics. Firstly, this review considers the diagnosis of prostate cancer through use of microfluidic systems and analyses the detection of prostate specific antigen, proteins, and circulating tumor cells to highlight the scope of current advancements. Secondly, this review analyses progressions in the understanding of prostate cancer physiology and considers techniques used to aid treatment of prostate cancer, such as the creation of a micro-environment. Finally, this review highlights potential future roles of microfluidics in assisting prostate cancer, such as in exosomal analysis. In conclusion, this review shows the vast scope and application of microfluidic systems and how these systems will ensure advancements to future prostate cancer management.

Identifiants

pubmed: 33934962
pii: S1078-1439(21)00120-4
doi: 10.1016/j.urolonc.2021.03.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

455-470

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Conflict of interests The authors declare no conflicts of interests

Auteurs

Darryl Ethan Bernstein (DE)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.

John Piedad (J)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.

Lara Hemsworth (L)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.

Alexander West (A)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.

Ian D Johnston (ID)

School of Physics, Engineering & Computer Science, University of Hertfordshire, UK.

Nikolay Dimov (N)

School of Physics, Engineering & Computer Science, University of Hertfordshire, UK.

Jameel M Inal (JM)

School of Life and Medical Sciences, University of Hertfordshire, UK; School of Human Sciences, London Metropolitan University, UK.

Nikhil Vasdev (N)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, UK. Electronic address: nikhilvasdev@doctors.org.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH